Pace Life Sciences Boosts Efficiency with Labguru Digital Integration in Laboratories

### Advancing Laboratory Efficiency: The Impact of Digital Integration at Pace® Life Sciences

Pace® Life Sciences, a leading contract development and manufacturing organization (CDMO), recently adopts Cenevo's Labguru platform to enhance its laboratory documentation processes. The Labguru platform offers a comprehensive, cloud-based laboratory data management system that incorporates features such as electronic lab notebooks (ELNs) and laboratory information management systems (LIMS). This strategic implementation allows Pace® to centralize operations, streamline workflows, and improve overall compliance within their analytical laboratories. Cynthia Hansen, IT Program Director at Pace®, underscores the platform’s scalability, signifying that it grows alongside the company’s evolving needs while bolstering client service through effective collaboration with the Labguru team.

The transition to Labguru’s digital workflows delivers several operational advantages. Key improvements include a significant reduction in manual data entry, which enhances the accuracy and integrity of laboratory data. Enhanced inventory visibility allows scientists at Pace® to prioritize critical tasks, steering away from cumbersome paper-based processes. Adam Michel, Senior ELN Specialist, emphasizes Labguru’s adaptability, highlighting its customizable features that align with Pace®’s unique operational framework. By fostering an environment of efficiency, this integration assures that Pace® Life Sciences remains well-positioned to meet regulatory standards while maintaining high-quality service across the pharmaceutical and biopharmaceutical sectors.

As the deployment of Labguru unfolds across four GMP analytical services laboratories, Pace® Life Sciences plans further expansion in alignment with its growth strategy. Gal Hasse, VP Product Labguru at Cenevo, expresses pride in the partnership, underscoring the role of advanced, AI-enabled platforms in scaling laboratory and manufacturing services. The collaboration not only enhances operational execution but also aligns with the overarching goal of ensuring quality and compliance in an increasingly competitive market.

In a parallel initiative within the Life Sciences sector, Agilisium announces a robust $5.5 million investment aimed at revolutionizing AI technology deployment in pharmaceutical and biotech companies. Its innovative model, dubbed “Forward Deployment Experts” (FDX), seeks to bridge the gap between AI capabilities and practical applications by embedding experts directly within client organizations. This approach aims to dismantle the barriers that hinder AI integration, such as insufficient combined expertise in technology and regulatory frameworks.

This strategic shift positions Agilisium as a frontrunner in the Life Sciences landscape. The initiative reflects the sector's evolving landscape as companies pivot toward AI-enhanced operations, reinforcing the importance of skilled talent in driving AI applications that deliver real-world results. As both Pace® Life Sciences and Agilisium initiate comprehensive digital transformations, they contribute to a larger trend steering the Life Sciences industry toward enhanced operational efficiency and innovation.